Mukai S, Mukai C, Asaoka K, Murakami S, Suzuki I
Kansenshogaku Zasshi. 1989 Feb;63(2):98-102. doi: 10.11150/kansenshogakuzasshi1970.63.98.
Dry syrup of Rokitamycin (RKM.DS), a new macrolide antibiotic with 16-membered ring developed by Toyo Jozo Co., Ltd., was used on cases of upper deep cervical lymphadenitis (UDCL) and of otitis media with exudatives (OME) likely caused by chlamydia infections, and its clinical effects were investigated. 1) In four cases of UDCL (C. psittaci infections), daily doses of 20.0-28.6 mg/kg were administered for 10-42 consecutive days and good efficacies were observed with two cases of excellent results and two cases of good results. 2) In one case of OME (C. trachomatis infection) a daily dose of 30.0 mg/kg was administered for 15 consecutive days and good effectiveness was observed. 3) No side effect was observed in any of the cases. From the above results, it became clear that RKM.DS could effectively used as a therapeutic agent for UDCL and OME in children.
由东洋酿造株式会社研发的新型 16 元环大环内酯类抗生素罗他霉素干糖浆(RKM.DS),用于治疗上颈部深层淋巴结炎(UDCL)以及可能由衣原体感染引起的渗出性中耳炎(OME),并对其临床疗效进行了研究。1)在 4 例 UDCL(鹦鹉热衣原体感染)患者中,每日剂量为 20.0 - 28.6 mg/kg,连续给药 10 - 42 天,观察到良好疗效,其中 2 例效果极佳,2 例效果良好。2)在 1 例 OME(沙眼衣原体感染)患者中,每日剂量为 30.0 mg/kg,连续给药 15 天,观察到良好疗效。3)所有病例均未观察到副作用。从上述结果可以看出,RKM.DS 可有效用作儿童 UDCL 和 OME 的治疗药物。